Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

By afschroeder • October 25, 2025

Lane AA, Papayannidis C, Angelucci E, McCloskey J, Schiller GJ, de la Fuente Burguera A, Montesinos P, Nagarwala Y, Herling M, Mannis G, Pemmaraju N. Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma. 2025 Oct 24:1-9. doi: 10.1080/10428194.2025.2557505. Epub ahead of print. PMID: 41134616.

Tags: Adverse effects, Blastic plasmacytoid dendritic cell neoplasm, capillary leak syndrome, Hematology/Oncology, Monitoring, Publications, symptom management, tagraxofusp

Related Posts

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer

Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La[...]

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchan J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]